🌱DEA Notice of Application for Bulk Manufacturing of Marihuana
The Drug Enforcement Administration (DEA) is providing notice of an application it has received from an entity applying to be registered to manufacture in bulk basic class(es) of controlled substances listed in schedule I. DEA intends to evaluate this and other pending applications according to its regulations governing the program of growing marihuana for scientific and medical research under DEA registration.
Learn More💊Notice of Application for Bulk Manufacturing by Promega Corporation
Promega Corporation has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More⚖️Restek Corporation's Import Application for Controlled Substances Notice
Restek Corporation has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Learn More🚫Revocation of DEA Registration for Physician in Georgia
The Drug Enforcement Administration has revoked Dr. Harvey Leslie's DEA registration due to his inability to prescribe controlled substances after the revocation of his Georgia medical license. The document outlines the regulatory process leading to this decision and the implications of default by the registrant.
Learn More💊Notice of Pharmaron's Application for Controlled Substances Manufacturing
Pharmaron Manufacturing Services (US), LLC has applied to be registered as a bulk manufacturer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Learn More💊SpecGx LLC's Application for Importing Controlled Substances
SpecGx LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Learn More💊Authorization of Production Activity for PCI Pharma in FTZ 35
The Department of Commerce's Foreign-Trade Zones Board has authorized production activity for PCI Pharma Services in FTZ 35, covering facilities in Croydon and Philadelphia, Pennsylvania. This authorization allows for specific production activities under established regulations, promoting operational efficiency and potential cost benefits for the pharmacy sector.
Learn More💊Notice of Controlled Substances Import Application by Pharmaron
Pharmaron Manufacturing Services (US) LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to SUPPLEMENTARY INFORMATION listed below for further drug information.
Learn More💊Implications of New Nonprescription Drug Regulations for Businesses
In accordance with the memorandum of January 20, 2025, from the President, entitled "Regulatory Freeze Pending Review," the effective date of the final rule, entitled "Nonprescription Drug Product With an Additional Condition for Nonprescription Use," (ACNU) was delayed until March 21, 2025. Additional time is needed for review; therefore, the delay is extended for an additional 60 days.
Learn More💊Fisher Clinical Services' Application for Controlled Substance Importation
Fisher Clinical Services, Inc. has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer to Supplementary Information listed below for further drug information.
Learn More